Research-use information only. This page summarises published literature on gonadorelin. Material supplied by Peptides Lab UK is for laboratory research use only, not for human or veterinary use, and nothing here is medical or dosing advice.
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — the ten-amino-acid decapeptide that the hypothalamus releases to drive the entire reproductive axis. Its defining property in research is that it is identical to native GnRH, which means it acts at the very top of the hypothalamic-pituitary-gonadal cascade, and its effect depends entirely on how it is administered. That last point is the single most important thing to understand about it.
What gonadorelin is
Gonadorelin is the synthetic form of endogenous GnRH, a decapeptide secreted by hypothalamic neurons into the hypophyseal portal system. Its very short half-life — minutes, not hours — is not a flaw but a functional feature: the native hormone is released in pulses, and pulsatility is central to how it works.
The pulsatile-versus-continuous distinction
This is the defining characteristic of GnRH pharmacology and the reason gonadorelin behaves so differently depending on delivery:
- Pulsatile administration — intermittent dosing mimics the natural rhythm and stimulates pituitary release of LH and FSH. The receptor stays responsive.
- Continuous administration — sustained exposure paradoxically suppresses the axis, because the GnRH receptor downregulates and desensitises. This is the mechanism behind long-acting GnRH agonists used clinically to shut down the axis.
The same molecule therefore produces opposite outcomes depending only on timing. Any research protocol that does not specify the delivery pattern is uninterpretable.
Where gonadorelin sits relative to related compounds
The reproductive axis has three intervention points, and confusing them invalidates study design:
- Gonadorelin (GnRH) — acts at the pituitary, stimulating endogenous LH and FSH release.
- Kisspeptin-10 — acts upstream at the hypothalamus, on the GnRH neurons themselves. See kisspeptin-10.
- HCG — acts downstream at the gonad, as an LH analogue, bypassing the pituitary entirely. See our HCG research reference.
In sequence: kisspeptin drives the hypothalamus, gonadorelin drives the pituitary, HCG drives the gonad. Gonadorelin is the only one of the three that requires an intact and responsive pituitary to have any effect.
Gonadorelin versus longer-acting GnRH analogues
Gonadorelin is native-sequence GnRH with a short half-life. Modified analogues such as triptorelin substitute amino acids to resist degradation, producing prolonged action — which, through the continuous-exposure mechanism above, drives suppression rather than stimulation. See triptorelin acetate. The distinction between native gonadorelin and a long-acting analogue is not a minor pharmacokinetic detail; it inverts the biological outcome.
Dosage as described in the research literature
Published protocols describe gonadorelin in microgram quantities, and — critically — specify the dosing interval as well as the dose, because interval determines whether the effect is stimulatory or suppressive. Reconstitution is with bacteriostatic water. Given the very short half-life, research designs studying stimulation typically use frequent small doses or pump-based delivery.
These figures describe research documentation only and are not instructions for human use. For volume calculations see our peptide reconstitution calculator.
Handling and stability
Gonadorelin is supplied lyophilised and reconstituted with bacteriostatic water. As a small linear peptide it is reasonably stable dry but, like most peptides, degrades in solution — refrigerate reconstituted material and avoid freeze-thaw cycling. For general handling see our bacteriostatic water guide.
The UK regulatory position
Gonadorelin supplied for laboratory research is not a licensed medicine in the UK in that context and is not approved for human consumption. Peptides Lab UK supplies it for research use only, correctly labelled. Insist on batch-specific Certificate of Analysis data; our quality-standards SOP sets out the testing applied to every batch.
Frequently asked questions
What is gonadorelin?
Synthetic gonadotropin-releasing hormone (GnRH), a ten-amino-acid decapeptide identical to the native hypothalamic hormone that drives the reproductive axis by stimulating pituitary LH and FSH release.
How does gonadorelin work?
It binds GnRH receptors on pituitary gonadotroph cells. Delivered in pulses it stimulates LH and FSH release; delivered continuously it suppresses the axis through receptor desensitisation. The delivery pattern determines the outcome.
What is the difference between gonadorelin and HCG?
Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH, and requires an intact pituitary. HCG acts directly at the gonadal LH receptor, bypassing the pituitary. They occupy different points in the same axis.
What is the difference between gonadorelin and triptorelin?
Gonadorelin is native-sequence GnRH with a short half-life. Triptorelin is a modified long-acting analogue; sustained exposure drives suppression rather than stimulation through receptor downregulation.
Why does gonadorelin have such a short half-life?
Because native GnRH is designed to act in pulses. The short half-life allows the sharp on-off signalling that pulsatile stimulation depends on.
Is gonadorelin legal in the UK?
Gonadorelin supplied for laboratory research, correctly labelled and not for human administration, is a distinct lawful category from its licensed medicinal use.
Disclaimer: this content is for educational and research purposes only. Gonadorelin supplied by Peptides Lab UK is not intended for human or veterinary use.
